Guggenheim Capital LLC Biomarin Pharmaceutical Inc Transaction History

Guggenheim Capital LLC

$14 Billion
Q3 2024

A detailed history of Guggenheim Capital LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Guggenheim Capital LLC holds 39,955 shares of BMRN stock, worth $2.57 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

39,955

Previous 41,322 3.31%

Holding current value

$2.57 Million

Previous $3.4 Million 17.46%

% of portfolio

0.02%

Previous 0.02%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$69.02 - $93.84 $94,350 - $128,279	-1,367 Reduced 3.31%	39,955 $2.81 Million
Q2 2024 Aug 14, 2024	SELL	$74.43 - $92.22 $352,053 - $436,200	-4,730 Reduced 10.27%	41,322 $3.4 Million
Q1 2024 May 14, 2024	BUY	$83.81 - $99.0 $376,055 - $444,213	4,487 Added 10.8%	46,052 $4.02 Million
Q4 2023 Feb 14, 2024	SELL	$76.22 - $98.51 $281,251 - $363,501	-3,690 Reduced 8.15%	41,565 $4.01 Million
Q3 2023 Nov 14, 2023	SELL	$85.07 - $94.48 $370,054 - $410,988	-4,350 Reduced 8.77%	45,255 $4 Million
Q2 2023 Aug 11, 2023	BUY	$86.68 - $100.3 $581,102 - $672,411	6,704 Added 15.63%	49,605 $4.3 Million
Q1 2023 May 10, 2023	SELL	$87.74 - $117.27 $439,050 - $586,819	-5,004 Reduced 10.45%	42,901 $4.17 Million
Q4 2022 Feb 14, 2023	BUY	$80.93 - $108.63 $163,802 - $219,867	2,024 Added 4.41%	47,905 $4.96 Million
Q3 2022 Nov 14, 2022	SELL	$82.16 - $96.94 $828,747 - $977,833	-10,087 Reduced 18.02%	45,881 $3.89 Million
Q2 2022 Aug 15, 2022	SELL	$71.48 - $86.85 $205,719 - $249,954	-2,878 Reduced 4.89%	55,968 $4.64 Million
Q1 2022 May 16, 2022	SELL	$74.28 - $92.69 $531,919 - $663,753	-7,161 Reduced 10.85%	58,846 $4.54 Million
Q4 2021 Feb 14, 2022	BUY	$71.72 - $91.47 $154,054 - $196,477	2,148 Added 3.36%	66,007 $5.83 Million
Q3 2021 Nov 15, 2021	BUY	$74.77 - $85.47 $74,545 - $85,213	997 Added 1.59%	63,859 $4.94 Million
Q2 2021 Aug 13, 2021	SELL	$75.51 - $84.79 $160,911 - $180,687	-2,131 Reduced 3.28%	62,862 $5.25 Million
Q1 2021 May 13, 2021	BUY	$74.73 - $90.69 $240,331 - $291,659	3,216 Added 5.21%	64,993 $4.91 Million
Q4 2020 Feb 16, 2021	SELL	$72.61 - $90.2 $3.38 Million - $4.2 Million	-46,553 Reduced 42.97%	61,777 $5.42 Million
Q3 2020 Nov 13, 2020	SELL	$71.87 - $131.03 $330,961 - $603,393	-4,605 Reduced 4.08%	108,330 $8.24 Million
Q2 2020 Aug 14, 2020	BUY	$79.55 - $124.22 $669,651 - $1.05 Million	8,418 Added 8.05%	112,935 $13.9 Million
Q1 2020 Jun 02, 2020	SELL	$71.37 - $96.85 $1.39 Million - $1.88 Million	-19,436 Reduced 15.68%	104,517 $8.83 Million
Q4 2019 Feb 14, 2020	BUY	$64.27 - $86.37 $647,777 - $870,523	10,079 Added 8.85%	123,953 $10.5 Million
Q3 2019 Nov 14, 2019	SELL	$67.4 - $85.11 $148,010 - $186,901	-2,196 Reduced 1.89%	113,874 $7.68 Million
Q2 2019 Aug 14, 2019	SELL	$80.35 - $93.9 $503,473 - $588,377	-6,266 Reduced 5.12%	116,070 $9.94 Million
Q1 2019 May 15, 2019	BUY	$84.2 - $98.62 $468,994 - $549,313	5,570 Added 4.77%	122,336 $10.9 Million
Q4 2018 Feb 14, 2019	SELL	$80.14 - $106.07 $508,167 - $672,589	-6,341 Reduced 5.15%	116,766 $9.94 Million
Q3 2018 Nov 14, 2018	SELL	$93.92 - $105.72 $528,957 - $595,415	-5,632 Reduced 4.37%	123,107 $11.9 Million
Q2 2018 Aug 14, 2018	SELL	$76.01 - $99.03 $278,424 - $362,746	-3,663 Reduced 2.77%	128,739 $12.1 Million
Q1 2018 May 15, 2018	BUY	$77.67 - $92.63 $150,990 - $180,072	1,944 Added 1.49%	132,402 $10.7 Million
Q4 2017 Feb 14, 2018	SELL	$80.76 - $95.13 $1.43 Million - $1.68 Million	-17,699 Reduced 11.95%	130,458 $11.6 Million
Q3 2017 Nov 14, 2017	BUY	$80.6 - $94.95 $11.9 Million - $14.1 Million	148,157	148,157 $13.8 Million

Others Institutions Holding BMRN

# of Institutions

636

Shares Held

178M

Call Options Held

2.01M

Put Options Held

1.28M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.9B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.

Account

Guggenheim Capital LLC Biomarin Pharmaceutical Inc Transaction History